Fertility-sparing Neoadjuvant Chemotherapy in >4cm Cervical Cancer with Dr. David Viveros-Carreño
IJGC Podcast - A podcast by BMJ Group
![](https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/bf/b8/e2/bfb8e2ad-d94e-47c0-3c1d-ea935a9cf3ae/mza_3287283981698921002.jpg/300x300bb-75.jpg)
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David Viveros-Carreño. Dr. Viveros-Carreño is a Gynecologic Oncologist at Instituto Nacional de Cancerología, Clínica Universitaria Colombia and Clínica Los Nogales in Bogotá, Colombia. Highlights: - Fertility-sparing surgery after neoadjuvant chemotherapy in cervical cancer >4 cm is feasible, but the evidence is limited and should be considered as an experimental intervention. - A complete pathological response occurred in 56% of patients. - At least one pregnancy was achieved in 67% of cases and 60% were pre-term deliveries.